Stop immune tolerance in lung cancer!

Symposium
Chairs: Philipp A. Schnabel (Homburg/Saar, Germany), Arnaud Scherpereel (Lille, France)
Aims: To update oncologists, pulmonologists, and thoracic surgeons regarding the new lung cancer treatment options as well as immunologists, pathologists, and researchers on the immune mechanisms in lung cancer, new research directions, and the methods that are used in practice to evaluate the anti-cancer responses and immune status of cancer patients.
Target audience: Oncologists, pulmonologists, thoracic surgeons, immunologists, pathologists, and researchers who are interested in the practical applications of immunotherapy and evaluation of immune status before treatment.
How to define the immune status of lung cancer patient
Joanna Domagala-Kulawik (Warsaw, Poland)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files
Reversing the suppression of T-cells: the role of monoclonal antibodies
Joachim Aerts (Rotterdam, Netherlands)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files